Company Profile
FUJIFILM Toyama Chemical Co., Ltd. is a Japan-based pharmaceutical manufacturer specializing in small molecule drugs, regenerative medical products and CDMO services, headquartered at 14-1, Kyobashi 2-Chome, Chuo-ku, Tokyo 104-0031, Japan. Founded in December 1968 as TOYAMA CHEMICAL CO., LTD., the company was relaunched on October 1, 2018 through the merger of Toyama Chemical and FUJIFILM RI Pharma Co., Ltd., a radiopharmaceutical developer. It operates as a wholly owned subsidiary of FUJIFILM Holdings Corporation (TYO: 4901), led by President and Representative Director Mitsuhiro Sato, serving hospitals, clinics and pharmaceutical partners across Japan and global markets. The company also operates manufacturing facilities in Toyama Prefecture, Japan.
Core Products ＆ Technologies
Approved Pharmaceutical Products
• Avigan® Tablets (favipiravir): An anti-influenza antiviral drug approved in Japan in 2014 for new or re-emerging influenza virus infections, selectively inhibiting viral RNA polymerase
• SAVYSCUS® Injection: An autologous synovial mesenchymal stem cell regenerative medical product approved by Japan＇s Ministry of Health, Labour and Welfare in May 2026 for meniscal injuries requiring meniscectomy, the first regenerative medical product approved in Japan for meniscal injury under the Pharmaceutical and Medical Device Act
Oncology Pipeline ＆ Drug Delivery Systems
• FF-10832: A liposomal formulation containing gemcitabine for advanced solid tumors, currently in U.S. Phase 2a study in combination with KEYTRUDA® (pembrolizumab), granted FDA Orphan Drug Designation for biliary tract cancer
• FF-10850: A liposomal formulation containing topotecan for advanced solid tumors, currently in U.S. Phase I clinical trial
CDMO ＆ Manufacturing Services
• Liposome ＆ LNP Formulation CDMO: End-to-end contract development and manufacturing services for liposome and lipid nanoparticle formulations at the 701 facility, Japan＇s first commercial liposome manufacturing plant
• mRNA ＆ Nucleic Acid CDMO: Integrated mRNA-to-LNP services including in vitro transcription, LNP formulation and fill-finish, supported by partnerships with Synplogen and TriLink BioTechnologies; non-clinical services launched in 2023 with plans to expand to clinical and commercial production
• Bio CDMO: Large-scale biopharmaceutical manufacturing at the Toyama Second Factory Plant 704, one of Japan＇s largest bio CDMO facilities with 5,000-liter and 2,000-liter mammalian cell culture bioreactors
• ADC Manufacturing (2027): One-stop antibody drug conjugate manufacturing services including antibody production, conjugation, filling and lyophilization, currently under construction at the Toyama site
Market Position ＆ Certifications
FUJIFILM Toyama Chemical holds a specialized position in the Japanese pharmaceutical and biopharmaceutical CDMO markets, competing with Takeda Pharmaceutical, Daiichi Sankyo and Astellas Pharma in domestic drug development, and Lonza and Thermo Fisher Scientific in CDMO services. Key strengths include:
• 55+ years of Japanese pharmaceutical manufacturing heritage
• Anti-infective expertise: The only company in Japan capable of manufacturing sterile penicillin antibiotic products
• DDS technology leadership: Proprietary liposome, LNP and micro-needle drug delivery systems leveraging FUJIFILM＇s nano-dispersion and materials science expertise
• Regulatory compliance: GMP-compliant facilities meeting Japanese, U.S. and European standards; FDA Orphan Drug Designation for FF-10832; GLP certification for iPS cell-derived cardiomyocyte extracellular field potential measurement
• Integrated healthcare solutions: Synergy with FUJIFILM Corporation＇s in vitro diagnostic devices and reagents to provide comprehensive diagnosis-to-treatment solutions
Corporate Timeline
1968 — Founded as TOYAMA CHEMICAL CO., LTD. in Japan
2008 — Acquired by FUJIFILM Holdings Corporation, becoming a consolidated subsidiary
2014 — Avigan® Tablets receive manufacturing and marketing approval in Japan as an anti-influenza drug
2018 — Merges with FUJIFILM RI Pharma Co., Ltd. to form FUJIFILM Toyama Chemical Co., Ltd.
2020 — 701 facility at Toyama Second Factory becomes operational as Japan＇s first commercial liposome manufacturing plant
2021 — Transfers radiopharmaceutical business to PeptiDream Inc.
2024 — Enters strategic alliance with Synplogen for mRNA therapeutic CDMO services; signs agreement with TriLink BioTechnologies for mRNA capping technology
2025 — Completes construction of Plant 704, one of Japan＇s largest bio CDMO facilities; files for approval of SAVYSCUS® Injection in Japan; announces approximately 10 billion yen investment to expand Toyama factory for ampicillin hydrate production
2026 — SAVYSCUS® Injection receives approval in Japan for meniscal injuries; begins ADC manufacturing facility construction at Toyama site; obtains GLP certification for drug testing with MEA method using iPS cell-derived cardiomyocytes
Target Markets ＆ Applications
• Infectious Disease Treatment: Avigan® for influenza antiviral therapy and government stockpile countermeasures
• Regenerative Orthopedics: SAVYSCUS® Injection for meniscus-preserving treatment of knee injuries in orthopedic and sports medicine practices
• Oncology Drug Development: Liposomal formulations FF-10832 and FF-10850 for pancreatic, biliary, ovarian and small cell lung cancers
• Biopharmaceutical CDMO: Contract manufacturing for mRNA, LNP, liposome, ADC and small molecule formulations serving global pharmaceutical and biotech clients
• Drug Discovery Support: Tailored CRO services utilizing iPS cell-derived cardiomyocyte evaluation systems and advanced research platforms
Contact Information
Global Headquarters
Address: 14-1, Kyobashi 2-Chome, Chuo-ku, Tokyo 104-0031, Japan
Manufacturing Facilities
Toyama Second Factory (701 ＆ 704 Plants): 1-8-70 Chiharazaki, Toyama-shi, Toyama Prefecture, Japan
Parent Company
FUJIFILM Holdings Corporation
Address: 7-3, Akasaka 9-chome, Minato-ku, Tokyo 107-0052, Japan
Stock: TYO: 4901
Website: fujifilm.com
Investor Relations: holdings.fujifilm.com/en/investors/
